Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Celldex Therapeutics (NQ: CLDX ) 39.93 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 39.93 Bid (Size) 16.05 (1) Ask (Size) 63.48 (1) Prev. Close 39.93 Today's Range 39.93 - 39.93 52wk Range 22.11 - 53.18 Shares Outstanding 66,287,596 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 7 Analysts Have This To Say About Celldex Therapeutics August 12, 2024 Via Benzinga CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 09, 2024 CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Performance YTD -1.19% -1.19% 1 Month +3.88% +3.88% 3 Month +18.77% +18.77% 6 Month -16.92% -16.92% 1 Year +43.94% +43.94% More News Read More Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 08, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session July 30, 2024 Via Benzinga Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket July 30, 2024 Via Benzinga Analyst Expectations For Celldex Therapeutics's Future July 16, 2024 Via Benzinga Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session July 30, 2024 Via Benzinga Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria July 29, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Analyst Expectations For Celldex Therapeutics's Future June 03, 2024 Via Benzinga Unveiling 4 Analyst Insights On Celldex Therapeutics May 07, 2024 Via Benzinga ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? July 28, 2024 Via Benzinga Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria July 16, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics to Present at Jefferies Healthcare Conference June 04, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 June 02, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis May 15, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 06, 2024 Via InvestorPlace Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update May 06, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria April 17, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference March 08, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference March 05, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares March 05, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday March 01, 2024 Via Benzinga Topics Stocks Exposures US Equities Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock February 29, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Celldex Therapeutics Announces Proposed Public Offering of Common Stock February 28, 2024 From Celldex Therapeutics, Inc. Via GlobeNewswire Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 26, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
